Citi raised the firm’s price target on Zenas BioPharma (ZBIO) to $46 from $27 and keeps a Buy rating on the shares. The company reported “strong” Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis that outperformed expectations, the analyst tells investors in a research note. Citi believes the bull case for obexelima is playing out.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma price target raised to $44 from $30 at H.C. Wainwright
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Zenas BioPharma Reports Positive Phase 2 Trial Results
- Zenas BioPharma says obexelimab met primary endpoint in Phase 2 MoonStone trial
- Zenas BioPharma files to sell 6.31M shares of common stock for holders